论文部分内容阅读
目的研究自体细胞因子诱导的杀伤细胞(CIK)细胞联合化疗治疗晚期非小细胞的疗效。方法59例患者分成A组(单用TP方案化疗)与B组(自体CIK联合TP方案治疗)。对两组的生活质量、免疫学反应、缓解率(RR)、无疾病进展时间与生存期进行观察比较。CIK细胞由自体外周血单个核细胞扩增培养产生。结果CIK细胞的数量与杀伤活性均在培养第14～21天形成到高峰。与A组相比,B组病人的免疫力与生活质量显著提高。结论自体CIK联合化疗治疗晚期非小细胞肺癌能有效改善患者的免疫功能。
Objective To study the efficacy of autologous cytokine-induced killer (CIK) cells combined with chemotherapy in the treatment of advanced non-small cell. Methods 59 patients were divided into group A (single TP chemotherapy) and group B (autologous CIK combined with TP regimen). The quality of life, immunological reaction, remission rate (RR), progression-free time and survival of the two groups were observed and compared. CIK cells are produced by autologous peripheral blood mononuclear cell expansion culture. Results The number of CIK cells and cytotoxic activity all reached the peak on the 14th to 21st days of culture. Compared with group A, the immunity and quality of life of group B patients significantly increased. Conclusions Autologous CIK combined with chemotherapy for advanced non-small cell lung cancer can effectively improve the immune function.